Belatacept-Resistant Rejection Is Associated With CD28⁺ Memory CD8 T Cells.

ABSTRACT: Recently, newer therapies have been designed to more specifically target rejection in an effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific reagent, is associated with superior patient survival and graft function compared with traditional therapy, but its adoption as a mainstay immunosuppressive therapy has been tempered by increased rejection rates. It is essential that the underlying mechanisms associated with this rejection be elucidated before belatacept is more widely used. To that end, we designed a study in a nonhuman primate kidney transplant model where animals were treated with either a belatacept- or a tacrolimus-based immunosuppressive regimen. Interestingly, we found that elevated pretransplant frequencies of CD28⁺ CD8^+<

SUBMITTER: Mathews DV 

PROVIDER: S-EPMC5573634 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature